Browse News
Filter News
Found 671,419 articles
-
GSK CEO Emma Walmsley may face some contentious opposition from key investors interested in forcing a management change following the planned investor update.
-
Arrowhead will conduct its activities through preclinical development stages, while Horizon will have sole responsibility for the clinical development and commercialization of the medicine.
-
Though the world is reopening, this pandemic is not over. Moderna continues expanding production to answer the call globally.
-
The new U.S. HQ for Neogene has the backing of biotech guru Arie Belldegrun, CEO of Kite Pharma. The company has leased 38,000 sq. ft. in two Santa Monica buildings.
-
FDA Action Alert: Incyte and Ascendis
6/21/2021
Incyte had a particularly big week scheduled with the U.S. FDA, which included two PDUFA dates and an advisory committee meeting. In addition, Ascendis had a target action date. -
Researchers at the virtual 7th Congress of the European Academy of Neurology consistently report significant, lingering cognitive and behavioral problems in multiple studies.
-
The U.S. CDC issued new guidance for long COVID, and the NIH is figuring out how to deal with the disease, while Tonix Pharma plans to develop TNX-102 SL.
-
Clinical Catch-Up: June 14-18
6/21/2021
It was another busy week of clinical trial announcements. Here’s a look. -
C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma
6/21/2021
– CFT7455 Demonstrated High Binding Affinity to Cereblon and Target Selectivity in Non-Hodgkin’s Lymphoma Cell Models, Producing Rapid and Deep Degradation of IKZF1/3 Proteins.
-
Kymera Therapeutics Presents New Preclinical Data for its IRAKIMiD Degrader KT-413 Demonstrating Strong Antitumor Activity as Both Monotherapy and in Combination in MYD88-mutant Lymphoma Models
6/21/2021
Data presented at the 16th ICML Meeting demonstrate KT-413’s potent antitumor activity as a monotherapy compared to a clinically active IRAK4 kinase inhibitor or a latest generation IMiD in MYD88-mutant mouse xenograft model.
-
CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2021
6/21/2021
CymaBay Therapeutics, Inc. today announced positive data from its previously completed Phase 2 study and the ENHANCE Phase 3 study of seladelpar in patients with primary biliary cholangitis.
-
Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy
6/21/2021
Immutep Limited announces it has signed an agreement to commence a new Phase I trial, called INSIGHT-003, to evaluate the combination of lead product candidate eftilagimod alpha.
-
Immutep Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings
6/21/2021
Immutep Limited is pleased to announce that it has received commitments for a A$60 million two-tranche private placement of new ordinary shares ( New Shares ) to professional, institutional and sophisticated investors ( Placement ).
-
Akero Therapeutics Presents Analyses at the 2021 International Liver Congress
6/21/2021
Akero Therapeutics, Inc. today announced additional analyses from its Phase 2a BALANCED study of efruxifermin (EFX) in NASH patients with F1-F3 fibrosis, which were presented in two posters at the 2021 International Liver Congress.
-
Syneos Health Accelerates Decentralized Clinical Trial Delivery, Unveils New Collaboration with Site Sponsors
6/21/2021
Syneos Health today expanded its Decentralized Clinical Trial capabilities to include a dedicated Decentralized Clinical Trials Site Advocacy Group, continuing the momentum for Decentralized Solutions demonstrated by the recent acquisition of Illingworth Research Group to move clinical trials closer to the patient.
-
Aligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS™ Molecule Drug Candidate ALG-010133
6/21/2021
- First clinical data presented for ALG-010133, which is in development for S-antigen reduction in chronic hepatitis B (CHB) patients -Presentations include nonclinical data from 3 other CHB programs.
-
Privia Health to be Added to Russell 2000 Index
6/21/2021
Privia Health Group, Inc. today announced that it is set to join the Russell 2000 ® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, 2021.
-
Theratechnologies Announces New Preclinical Findings for Its Lead Investigational Peptide-Drug Conjugate TH1902 for the Potential Treatment of Metastatic Cancers
6/21/2021
Theratechnologies Inc. today announced new preclinical in vivo findings on the anti-metastatic effect and tolerability of its novel investigational proprietary peptide-drug conjugate (PDC), TH1902.
-
Dave Johnson Joins Biosplice Therapeutics Board of Directors
6/21/2021
Biosplice Therapeutics, Inc. announced today the addition of Dave Johnson, most recently Founder and CEO of VelosBio, as an independent director to its board.
-
Prometheus Biosciences Achieves Milestone Payment from Dr. Falk Pharma GmbH Further Validating the Prometheus360™ Platform
6/21/2021
Prometheus Biosciences, Inc. today announced it has received a $10 million milestone payment from Dr. Falk Pharma GmbH under its collaboration agreement to develop and commercialize Prometheus’ second program, PR600.